<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835441</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-A03</org_study_id>
    <nct_id>NCT04835441</nct_id>
  </id_info>
  <brief_title>ALPN-101 in Systemic Lupus Erythematosus</brief_title>
  <acronym>Synergy</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Phase 2, multinational, randomized, blinded study to evaluate the safety,&#xD;
      tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 in&#xD;
      adults with moderate to severe active systemic lupus erythematosus (SLE)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From study Day 1 until End of Study (28 weeks)</time_frame>
    <description>Type, incidence, and severity of adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>ALPN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-101</intervention_name>
    <description>Blinded ALPN-101 will be administered</description>
    <arm_group_label>ALPN-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blinded placebo matching ALPN-101 will be administered.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18 to 65&#xD;
&#xD;
          -  Diagnosis of lupus for ≥ 6 months prior to Screening&#xD;
&#xD;
          -  Positive ANA and/or elevated anti-dsDNA and/or elevated anti-Smith antibody test at&#xD;
             Screening&#xD;
&#xD;
          -  Active lupus at Screening and Baseline, as defined per-protocol and confirmed by the&#xD;
             study's medical monitor, including a SLEDAI score at Screening of ≥ 6 and a clinical&#xD;
             score at Baseline of ≥ 4&#xD;
&#xD;
          -  Standard lupus medications must be stable prior to Screening&#xD;
&#xD;
          -  Women must have a PAP smear and known HPV status within 12 months of Day 1&#xD;
&#xD;
          -  All participants must use highly effective birth control if they/their partner are&#xD;
             capable of becoming pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life-threatening or organ system-threatening lupus activity that is anticipated to&#xD;
             require increased treatment during the study&#xD;
&#xD;
          -  Proteinuria consistent with nephrotic syndrome&#xD;
&#xD;
          -  Active lupus-related neuropsychiatric disease&#xD;
&#xD;
          -  Drug-induced lupus&#xD;
&#xD;
          -  Any serious health condition that would place the subject at undue risk from the study&#xD;
             or would confound interpretation of safety or efficacy outcomes&#xD;
&#xD;
          -  Recent or serious ongoing infection; risk or history of serious infection&#xD;
&#xD;
          -  Receipt of live vaccination within 8 weeks of Day 1, or expected to require live&#xD;
             vaccination during the study&#xD;
&#xD;
          -  Unacceptable Screening laboratory results&#xD;
&#xD;
          -  History of new, ongoing, or recurrent malignancy ≤ 5 years prior to Day 1, with some&#xD;
             exceptions per-protocol&#xD;
&#xD;
          -  Pregnant or breastfeeding at the time of screening, or plans to become pregnant ≤ 3&#xD;
             months following the last dose of study drug&#xD;
&#xD;
          -  Prior diagnosis of, or fulfills diagnostic criteria for, another rheumatic disease&#xD;
             that overlaps with lupus or another autoimmune or inflammatory disease that may&#xD;
             confound clinical assessments or increase subject risk in the study&#xD;
&#xD;
          -  Diagnosis of, or fulfills diagnostic criteria for, fibromyalgia&#xD;
&#xD;
          -  Functional class IV lupus&#xD;
&#xD;
          -  Does not meet protocol washout periods for concomitant medications&#xD;
&#xD;
          -  Serious lupus disease activity, which warrants immediate immunosuppressive therapy not&#xD;
             appropriate for the study or which makes the possibility of receiving placebo or&#xD;
             investigational agent an inappropriate risk&#xD;
&#xD;
          -  Ongoing participation in another therapeutic clinical trial&#xD;
&#xD;
          -  Known hypersensitivity to ALPN-101, components thereof, or excipients contained in the&#xD;
             drug formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Hillson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hansi Kumari</last_name>
    <phone>+1 754-251-9765</phone>
    <email>kumari.hansi@parexel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site (107)</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (158)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (155)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (109)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (169)</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (106)</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (170)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (120)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Sites (134, 153)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (152)</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (151)</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (131)</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (163)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (114)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (173)</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (154)</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (138)</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (164)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (115)</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (112)</name>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <zip>38555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (145)</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (171)</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (143)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (118)</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (166)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (121)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (104)</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (162)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Junggu</city>
        <state>Daegu</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD28</keyword>
  <keyword>ICOS</keyword>
  <keyword>Autoimmune disease</keyword>
  <keyword>Immune system disease</keyword>
  <keyword>Immunosuppressive agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

